SYH2069 / CSPC Pharma - LARVOL DELTA

…CSPC Pharmaceutical…is pleased to announce that GLP-1/GIP receptor dual-biased agonist polypeptide injection (SYH2069 Injection) (the 'Product') developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China (HKEXnews) - "The indication for this clinical trial approval is weight management for individuals with obesity or overweight and at least one weight-related comorbidity."

New trial • Obesity

GLP-1/GIP receptor dual-biased agonist polypeptide injection (SYH2069 injection) obtains clinical trial approval in the U.S. (CSPC Press Release)

IND • Obesity